Episode Details

## Chapters 0:00 The Madrigal Pharmaceuticals Story 3:48 Earnings Overview Madrigal Pharmaceuticals just reported Q1 2026 earnings — eps beats, revenue misses. The mixed results raise questions — here's our full breakdown of what it means for MDGL. 🔔 Subscribe for weekly deep dives on every Russell 1000 earnings report: https://www.youtube.com/@ChargedAlpha?sub_confirmation=1 📊 Key Financial Highlights: • Revenue: $311M • EPS: $-3.25 vs $-3.61 expected (-10.0% beat) 📈 Free stock screening tools — no signup, no paywall: https://chargedalpha.com 🎧 Also available as a podcast: https://chargedalpha.podbean.com #stocks #MDGL #earnings #stocks #investing #stockmarket #earningsseason #wallstreet #MadrigalPharmaceuticals --- Financial data and charts: Financial Modeling Prep (https://financialmodelingprep.com) ⚖️ Disclaimer: This video is for informational and educational purposes only. Nothing discussed constitutes a buy, sell, or hold recommendation. All investments carry risk. Past performance does not guarantee future results. Always do your own research and consult a qualified financial advisor. Hosts may hold positions in securities discussed. This episode was researched, written, and produced using AI-assisted tools. Data sourced from public filings and may contain inaccuracies. Watch on YouTube: https://www.youtube.com/watch?v=xNheejtx3So